Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer

Status Terminated

Clinical Trial Summary

The purpose of this study is to evaluate progression free survival primarily. The secondary objectives are to evaluate the antitumor activity, as assessed by objective tumor response, duration of clinical benefit, overall survival, and the safety profile of TAS-109

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00824161
Study type	Interventional
Source	Taiho Pharmaceutical Co., Ltd.
Contact
Status	Terminated
Phase	Phase 2
Start date	January 2009
Completion date	December 2010

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05028933` - IMC001 for Clinical Research on Advanced Digestive System Malignancies	Phase 1
Recruiting	`NCT06200363` - A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer	Phase 1
Not yet recruiting	`NCT02923622` - Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer	N/A
Completed	`NCT01723969` - Screening Platform for Clinical Trials in Advanced Colorectal Cancer
Active, not recruiting	`NCT00309179` - A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors	Phase 2
Completed	`NCT03699111` - Identification of New Patient Stratification Tools in MSS RAS mt mCRC
Not yet recruiting	`NCT02826837` - LEAC-102 for Advanced Colorectal Cancer	Phase 1/Phase 2
Recruiting	`NCT05077839` - Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC	Phase 2
Recruiting	`NCT04324476` - A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer	Phase 2
Not yet recruiting	`NCT06369259` - Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer	Phase 2
Completed	`NCT00707889` - Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer	Phase 2
Terminated	`NCT01271166` - Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer	Phase 1
Completed	`NCT00386828` - Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial	Phase 2
Recruiting	`NCT04764006` - Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study	Phase 2
Active, not recruiting	`NCT04835324` - Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
Active, not recruiting	`NCT02619435` - Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer	Phase 2
Completed	`NCT01822444` - ANGIOPREDICT. ICORG 12-16, V3
Completed	`NCT00498407` - A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer	Phase 2
Recruiting	`NCT05731336` - A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.
Active, not recruiting	`NCT04744831` - Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer	Phase 2